Analyst firms · H.C. Wainwright · TBPH
H.C. Wainwright TBPH price target and rating history
Theravance Biopharma Inc. (TBPH) · Health Care
H.C. Wainwright rates Theravance Biopharma Inc. (TBPH) Buy with a $12 price target, as of its latest action on Feb 24, 2022. It has published 3 rating actions on TBPH since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $12
- Median target, all firms
- Too few
- Actions on TBPH
- 3
H.C. Wainwright price target on TBPH
Every H.C. Wainwright rating on TBPH
- Feb 24, 2022
- Sep 16, 2021
- Aug 24, 2021
How other firms rate TBPH
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Perform | $27 | Mar 5, 2026 |
| B. Riley Securities | Neutral | $14 | Mar 4, 2026 |
Questions about H.C. Wainwright and TBPH
- What is H.C. Wainwright's price target for TBPH?
- H.C. Wainwright's latest stated price target for Theravance Biopharma Inc. (TBPH) is $12, from its action on Feb 24, 2022.
- What is H.C. Wainwright's rating on TBPH?
- H.C. Wainwright rates TBPH Buy, a bullish rating, as of Feb 24, 2022.
- When did H.C. Wainwright last change its view on TBPH?
- On Feb 24, 2022, H.C. Wainwright raises its price target to $12 from $8, keeps Buy.
More TBPH rating histories
All H.C. Wainwright ratingsTBPH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.